Dyno Therapeutics

Machine-guided design to enable gene therapy

At Dyno Therapeutics we are expanding the boundaries of gene therapy by accelerating the transition of genetic medicine from the lab to the clinic for the treatment of millions of patients.

Capsids derived from Adeno-associated virus (AAV) are the vector of choice for gene therapy, yet even the most widely used versions are not optimal for disease treatment. There has not been a systematic way to achieve multi-functional, disease-specific enhancement of AAV capsids - until now.

Dyno’s groundbreaking engineering platform combines machine learning with next-gen DNA synthesis and high-throughput DNA sequencing to program capsids with improved functions like precision delivery and immune system evasion, overcoming the barriers that separate gene therapy research from real-world therapies.

Our goals are common. Our approach is not. Together, we aim to deliver innovative treatments that fulfill the promise of genetic medicine.

Our capsid engineering platform

Learn about the science behind Dyno from recent publications by Dyno co-authors:

Synthesis of DNA libraries encoding modified capsids

We design millions of capsid sequences, which are then synthesized on DNA printers and assembled into capsid libraries, ready for testing.

High-throughput measurement of capsid properties

Using next-generation sequencing, we track DNA barcodes identifying individual capsid variants within our libraries. In pooled experiments with millions of capsids, we simultaneously measure numerous properties important for therapeutic success.

Machine learning models of capsid fitness landscape

We train machine learning models to predict the function of new sequences, building out a map of the AAV capsid fitness landscape. With every new experiment our map becomes bigger and more detailed.

Climbing the fitness landscape toward optimized AAV capsids

Balancing between exploration and optimization, we efficiently search the fitness landscape for improved capsids. Our optimized capsids make current gene therapies more effective and enable the treatment of new diseases by targeting capsids to new organs and cell types.

Iterative cycles for ever-improving gene therapy

Repeating these steps allows us to build on the lessons and successes of previous experiments, train better models, and further climb the fitness landscape for vectors with desired properties, including in vivo delivery efficiency and specificity, immune evasion, packaging size and manufacturability.